Extracellular Matrix Deposition and Remodeling After Corneal Alkali Burn in Mice
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
The Skin in the Ehlers-Danlos Syndromes
EDS Global Learning Conference July 30-August 1, 2019 (Nashville) The Skin in the Ehlers-Danlos Syndromes Dr Nigel Burrows Consultant Dermatologist MD FRCP Department of Dermatology Addenbrooke’s Hospital Cambridge University NHS Foundation Trust Cambridge, UK No conflict of interests or disclosures Burrows, N: The Skin in EDS 1 EDS Global Learning Conference July 30-August 1, 2019 (Nashville) • Overview of skin and anatomy • Skin features in commoner EDS • Skin features in rarer EDS subtypes • Skin management The skin • Is useful organ to sustain life ØProtection - microorganisms, ultraviolet light, mechanical damage ØSensation ØAllows movement ØEndocrine - vitamin D production ØExcretion - sweat ØTemperature regulation Burrows, N: The Skin in EDS 2 EDS Global Learning Conference July 30-August 1, 2019 (Nashville) The skin • Is useful organ to sustain life • Provides a visual clue to diagnoses • Important for cultures and traditions • Ready material for research Skin Fun Facts • Largest organ in the body • In an average adult the skin weighs approx 5kg (11lbs) and covers 2m2 (21 sq ft) • 11 miles of blood vessels • The average person has about 300 million skin cells • More than half of the dust in your home is actually dead skin • Your skin is home to more than 1,000 species of bacteria Burrows, N: The Skin in EDS 3 EDS Global Learning Conference July 30-August 1, 2019 (Nashville) The skin has 3 main layers Within the Dermis Extracellular Matrix 1. Collagen 2. Elastic fibres 3. Ground Substances i) glycosaminoglycans, ii) proteoglycans, -
Aging and the Cornea
814 British Journal of Ophthalmology 1997;81:814–817 Br J Ophthalmol: first published as 10.1136/bjo.81.10.814 on 1 October 1997. Downloaded from BRIEF REVIEWS ON ASPECTS OF AGING AND THE EYE Aging and the cornea RGAFaragher, B Mulholland, S J Tuft, S Sandeman, P T Khaw Aging, the persistent decline in age specific fitness of an also known as contact inhibition. Rather confusingly, both organism as a result of internal physiological deterioration, senescence and quiescence are referred to as the G0 phase is a common process among multicellular organisms.1 In of the cell cycle (sometimes more helpfully distinguished as humans, aging is usually monitored in relation to time, G0Q and G0S).15 Senescence is also distinct from cell which renders it diYcult to diVerentiate between time death, occurring either by apoptosis or necrosis, and it is dependent biological changes and damage from environ- not a form of terminal diVerentiation.16 17 The phenotypes mental insults. There are essentially three types of aging at of growth and senescence are totally distinct cell cycle work in any adult tissue; the aging of long lived proteins, compartments; there is no such thing as a half senescent the aging of dividing cells, and the aging of non-dividing cell. Cells that enter replicative senescence acquire two cells.2 Dividing cells may be derived from renewing popu- phenotypes: they leave the cell cycle with a G1 DNA lations in which the rate of cell loss and division is great. An content,18 and they undergo a characteristic series of example is the corneal epithelium in which complete changes in biology and gene expression that alters the turnover occurs within 5–7 days after terminal function of the cell.13 19 In this latter situation some genes diVerentiation.34 Conditional renewal populations, which are transcriptionally repressed, some gene expression is normally have an extremely low proliferation rate, can also upregulated, and some totally senescent specific genes are produce dividing cells in response to extrinsic stimuli. -
Corneal Cell Therapy: with Ipscs, It Is No More a Far-Sight Koushik Chakrabarty1* , Rohit Shetty2 and Arkasubhra Ghosh1
Chakrabarty et al. Stem Cell Research & Therapy (2018) 9:287 https://doi.org/10.1186/s13287-018-1036-5 REVIEW Open Access Corneal cell therapy: with iPSCs, it is no more a far-sight Koushik Chakrabarty1* , Rohit Shetty2 and Arkasubhra Ghosh1 Abstract Human-induced pluripotent stem cells (hiPSCs) provide a personalized approach to study conditions and diseases including those of the eye that lack appropriate animal models to facilitate the development of novel therapeutics. Corneal disease is one of the most common causes of blindness. Hence, significant efforts are made to develop novel therapeutic approaches including stem cell-derived strategies to replace the diseased or damaged corneal tissues, thus restoring the vision. The use of adult limbal stem cells in the management of corneal conditions has been clinically successful. However, its limited availability and phenotypic plasticity necessitate the need for alternative stem cell sources to manage corneal conditions. Mesenchymal and embryonic stem cell-based approaches are being explored; nevertheless, their limited differentiation potential and ethical concerns have posed a significant hurdle in its clinical use. hiPSCs have emerged to fill these technical and ethical gaps to render clinical utility. In this review, we discuss and summarize protocols that have been devised so far to direct differentiation of human pluripotent stem cells (hPSCs) to different corneal cell phenotypes. With the summarization, our review intends to facilitate an understanding which would allow developing efficient and robust protocols to obtain specific corneal cell phenotype from hPSCs for corneal disease modeling and for the clinics to treat corneal diseases and injury. Keywords: Cornea, Induced pluripotent stem cells, Differentiation, Disease modeling, Cell replacement therapy Background using viral vectors. -
Phenotype and Response to Growth Hormone Therapy in Siblings with B4GALT7 Deficiency T ⁎ Carla Sandler-Wilsona, Jennifer A
Bone 124 (2019) 14–21 Contents lists available at ScienceDirect Bone journal homepage: www.elsevier.com/locate/bone Case Report Phenotype and response to growth hormone therapy in siblings with B4GALT7 deficiency T ⁎ Carla Sandler-Wilsona, Jennifer A. Wambacha, , Bess A. Marshalla,b, Daniel J. Wegnera, William McAlisterc, F. Sessions Colea,b, Marwan Shinawia a Edward Mallinckrodt Department of Pediatrics, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, MO 63110, USA b Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, MO 63110, USA c Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, MO 63110, USA ARTICLE INFO ABSTRACT Keywords: B4GALT7 encodes beta-1,4-galactosyltransferase which links glycosaminoglycans to proteoglycans in connective B4GALT7 tissues. Rare, biallelic variants in B4GALT7 have been associated with spondylodysplastic Ehlers-Danlos and Spondylodysplastic Ehlers-Danlos syndrome Larsen of Reunion Island syndromes. Thirty patients with B4GALT7-related disorders have been reported to date Larsen of Reunion Island syndrome with phenotypic variability. Using whole exome sequencing, we identified male and female siblings with bial- Growth hormone lelic, pathogenic B4GALT7 variants and phenotypic features of spondylodysplastic Ehlers-Danlos syndrome as Proteoglycan well as previously unreported skeletal characteristics. We also provide detailed radiological -
Pathophysiological Significance of Dermatan Sulfate Proteoglycans Revealed by Human Genetic Disorders
Title Pathophysiological Significance of Dermatan Sulfate Proteoglycans Revealed by Human Genetic Disorders Author(s) Mizumoto, Shuji; Kosho, Tomoki; Yamada, Shuhei; Sugahara, Kazuyuki Pharmaceuticals, 10(2), 34 Citation https://doi.org/10.3390/ph10020034 Issue Date 2017-06 Doc URL http://hdl.handle.net/2115/67053 Rights(URL) http://creativecommons.org/licenses/by/4.0/ Type article File Information pharmaceuticals10-2 34.pdf Instructions for use Hokkaido University Collection of Scholarly and Academic Papers : HUSCAP pharmaceuticals Review Pathophysiological Significance of Dermatan Sulfate Proteoglycans Revealed by Human Genetic Disorders Shuji Mizumoto 1,*, Tomoki Kosho 2, Shuhei Yamada 1 and Kazuyuki Sugahara 1,* 1 Department of Pathobiochemistry, Faculty of Pharmacy, Meijo University, 150 Yagotoyama, Tempaku-ku, Nagoya 468-8503, Japan; [email protected] 2 Center for Medical Genetics, Shinshu University Hospital, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan; [email protected] * Correspondence: [email protected] (S.M.); [email protected] (K.S.); Tel.: +81-52-839-2652 Academic Editor: Barbara Mulloy Received: 22 February 2017; Accepted: 24 March 2017; Published: 27 March 2017 Abstract: The indispensable roles of dermatan sulfate-proteoglycans (DS-PGs) have been demonstrated in various biological events including construction of the extracellular matrix and cell signaling through interactions with collagen and transforming growth factor-β, respectively. Defects in the core proteins of DS-PGs such as decorin and -
J·-·. Universidad
Universidad ,.,. I ::::.�j:.� �·-·. :::t.,.•• de Alcala COMISIÓN DE ESTUDIOS OFICIALES DE POSGRADO Y DOCTORADO ACTA DE EVALUACIÓN DE LA TESIS DOCTORAL Año académico 2016/17 DOCTORANDO: RODRÍGUEZ PÉREZ, MARÍA ISABEL D.N.1./PASAPORTE: ****779T PROGRAMA DE DOCTORADO: D325 DOCTORADO EN CIENCIAS DE LA SALUD DEPARTAMENTO DE: CIRUGÍA, CIENCIAS MÉDICAS Y SOCIALES TITULACIÓN DE DOCTOR EN: DOCTOR/A POR LA UNIVERSIDAD DE ALCALÁ En el día de hoy 13/09/17, reunido el tribunal de evaluación nombrado por la Comisión de Estudios Oficiales de Posgrado y Doctorado de la Universidad y constituido por los miembros que suscriben la presente Acta, el aspirante defendió su Tesis Doctoral, elaborada bajo la dirección de MIGUEL ÁNGEL TESUS GUEZALA // JUAN GROS OTERO. o < -o Sobre el siguiente tema: SEGURIDAD, EFICACIA Y PREDICTIBILIDAD EN CIGURÍA CON LÁSER EXCIMER: LASIK z MECÁNICO, LASIK FEMTOSEGUNDOY LASEK < ::,; ::, :,: Finalizada la defensa y discusión de la tesis, el tribunal acordó otorgar la CALIFICACIÓN GLOBAL6 de (no apto, < ..J aprobado, notable y sobresaliente): ____5 _t0_S_�_'.f,_o_(/2_�_1C___________ ____ o"' o z o ::,; Alcalá de Henares, .. Á.J..... de .. ?.fp.h...�-�- de _'!:-:!__1)- -< ..J< u ..J< "' EL PRESIDENTE EL SECRETARIO EL VOCAL o o < o "'- """' > z ::, Con fccha_� __ dc_�e.___de � lTia Comisión Delegada de la Comisión de Estudios Oficialesde Posgrado, a la vista de los votos emitidos de manera anónima por el tribunal que ha juzgado la tesis, resuelve: � Conceder la Mención de "Cum Laude" O No conceder la Mención de "Cum Laude" La Secretariade la Comisión Delegada 6 La calificación podrá ser "no apto" "aprobado" "notable" y "sobresaliente". -
CVN De FECYT Fecha Del Documento: 15/01/2020 V 1.4.0 733513B2ee09064ccf5bd412636c83db
Miguel Angel Teus Guezala Generado desde: Editor CVN de FECYT Fecha del documento: 15/01/2020 v 1.4.0 733513b2ee09064ccf5bd412636c83db Este fichero electrónico (PDF) contiene incrustada la tecnología CVN (CVN-XML). La tecnología CVN de este fichero permite exportar e importar los datos curriculares desde y hacia cualquier base de datos compatible. Listado de Bases de Datos adaptadas disponible en http://cvn.fecyt.es/ 733513b2ee09064ccf5bd412636c83db Resumen libre del currículum Descripción breve de la trayectoria científica, los principales logros científico-técnicos obtenidos, los intereses y objetivos científico-técnicos a medio/largo plazo de la línea de investigación. Incluye también otros aspectos o peculiaridades importantes. Catedrático de Universidad del área de conocimiento de Oftalmología, adscrito al Departamento de Cirugía de la Facultad de Medicina de la Universidad de Alcalá. Patrono de la Fundación de Investigación Biomédica del Hospital Príncipe de Asturias, desde 2005. Coordinador del grado de optometría en el centro CUNIMAD, adscrito a la UAH (desde julio 2019). Su trayectoria investigadora se orienta en torno a tres líneas principales: Cirugía refractiva láser corneal, biomecánica corneal y el glaucoma. Ha participado en múltiples proyectos de investigación, entre sus publicaciones destaca la producción en artículos en revistas internacionales y los capítulos de libro editados por instituciones y editoriales de reconocido prestigio internacional, como es el caso de la Agencia Laín Entralgo de la Comunidad de Madrid o Elsevier. Es miembro evaluador de trabajos científicos de diversas revistas nacionales e internacionales. Ha dirigido un total de 29 Tesis Doctorales (entre los años 2003 a 2019). Ha sido director externo en el Máster Universitario en Optometría Clínica de la Universidad Europea de Madrid. -
The Stroma and Keratoconus: a Review
S Afr Optom 2007 66(3) 87-93 The stroma and keratoconus: a review WDH Gillan* Optometric Science Research Group, Department of Optometry, University of Johannesburg, PO Box 524, Auckland Park, 2006 South Africa <[email protected]> Introduction The cornea is the transparent anterior portion of the fibrous coat of the eye1. In humans the cornea averages 0.52 mm in thickness centrally thickening to 0.65 mm in the periphery2-5. The human cornea consists of five layers: the epithelium, Bowman’s membrane, the stroma, Descemets’s membrane and the endothelium2-5. The stroma makes up approximately 90% of the thickness of the cornea and is the major structural component. The cornea’s strength, shape and transparency can be attributed to the anatomic and metabolic properties of the stroma3, 4. The stroma consists of collagen, glycosaminoglycans, keratocytes and nerves. Two to three percent of the stroma consists of cellular components (keratocytes). Collagen makes up approximately 70% of the dry weight of the cornea. Type I collagen makes up the majority of the collagen in the stroma with types III, IV and VI also being present4. Keratoconus is a developmental or dystrophic deformity of the cornea in which it becomes cone-shaped due to thinning and stretching of the tissue in its central area1. Depending on the diagnostic criteria used, keratoconus has a prevalence between 50 and 230 people per 100 000.4 Keratoconus occurs in all races and there is no gender preference4. An association between connective tissue disease and keratoconus has been suggested4. Connective tissue diseases like Ehlers-Danlos syndrome, Marfans’ syndrome, osteogenesis imperfecta, Reiger’s syndrome, among others, have been associated with keratoconus4, 6. -
Quantitative Analysis of Corneal Microstructure in Keratoconus KH Weed Et Al 615
Eye (2007) 21, 614–623 & 2007 Nature Publishing Group All rights reserved 0950-222X/07 $30.00 www.nature.com/eye 1 1 1 CLINICAL STUDY Quantitative KH Weed , CJ MacEwen , A Cox and CNJ McGhee2 analysis of corneal microstructure in keratoconus utilising in vivo confocal microscopy Abstract presence of keratoconus did not affect the endothelial cell density (P ¼ 0.54). Purpose To establish and quantify the in vivo Conclusion In vivo confocal microscopy confocal microscopic features of moderate to can provide insight into the microstructural advanced keratoconus. changes that occur in keratoconus. Methods Nineteen keratoconus subjects were Eye (2007) 21, 614–623. doi:10.1038/sj.eye.6702286; catergorised using Orbscan-derived corneal published online 24 February 2006 apex power and pachymetry as exhibiting moderate (n ¼ 7) and advanced (n ¼ 12) Keywords: in vivo confocal microscopy; keratoconus. Control subjects included 23 keratoconus; cornea; contact lens noncontact lens wearers (Group A) and 15 contact lens wearers (Group B). All subjects Introduction underwent Confoscan slit scanning in vivo confocal microscopy. Keratoconus is a noninflammatory corneal Results Compared with Group A ectasia which is usually bilateral and 1 (49127434 cells/mm2), basal epithelial density progressive. The incidence of this ocular 1Ophthalmology was significantly lower in both moderate disease is approximately 1 per 2000 in the 2 Department, Ninewells (45927414 cells/mm2, Po0.05) and advanced general population ; however, the precise 3 Hospital and Medical keratoconus -
CORNEAL ULCERS Diagnosis and Management
CORNEAL ULCERS Diagnosis and Management System requirement: • Windows XP or above • Power DVD player (Software) • Windows Media Player 10.0 version or above • Quick time player version 6.5 or above Accompanying DVD ROM is playable only in Computer and not in DVD player. Kindly wait for few seconds for DVD to autorun. If it does not autorun then please do the following: • Click on my computer • Click the drive labelled JAYPEE and after opening the drive, kindly double click the file Jaypee CORNEAL ULCERS Diagnosis and Management Namrata Sharma MD DNB MNAMS Associate Professor of Ophthalmology Cornea, Cataract and Refractive Surgery Services Dr. Rajendra Prasad Centre for Ophthalmic Sciences All India Institute of Medical Sciences, New Delhi India Rasik B Vajpayee MS FRCSEd FRANZCO Head, Corneal and Cataract Surgery Centre for Eye Research Australia Royal Victorian Eye and Ear Hospital University of Melbourne Australia Forewords Hugh R Taylor Peter R Laibson ® JAYPEE BROTHERS MEDICAL PUBLISHERS (P) LTD New Delhi • Ahmedabad • Bengaluru • Chennai • Hyderabad • Kochi • Kolkata • Lucknow • Mumbai • Nagpur Published by Jitendar P Vij Jaypee Brothers Medical Publishers (P) Ltd B-3 EMCA House, 23/23B Ansari Road, Daryaganj New Delhi 110 002, India Phones: +91-11-23272143, +91-11-23272703, +91-11-23282021, +91-11-23245672 Rel: +91-11-32558559, Fax: +91-11-23276490, +91-11-23245683 e-mail: [email protected] Visit our website: www.jaypeebrothers.com Branches • 2/B, Akruti Society, Jodhpur Gam Road Satellite Ahmedabad 380 015, Phones: +91-79-26926233, -
The Ehlers-Danlos Syndromes, Rare Types
American Journal of Medical Genetics Part C (Seminars in Medical Genetics) 175C:70–115 (2017) RESEARCH REVIEW The Ehlers–Danlos Syndromes, Rare Types ANGELA F. BRADY, SERWET DEMIRDAS, SYLVIE FOURNEL-GIGLEUX, NEETI GHALI, CECILIA GIUNTA, INES KAPFERER-SEEBACHER, TOMOKI KOSHO, ROBERTO MENDOZA-LONDONO, MICHAEL F. POPE, MARIANNE ROHRBACH, TIM VAN DAMME, ANTHONY VANDERSTEEN, CAROLINE VAN MOURIK, NICOL VOERMANS, JOHANNES ZSCHOCKE, AND FRANSISKA MALFAIT * Dr. Angela F. Brady, F.R.C.P., Ph.D., is a Consultant Clinical Geneticist at the North West Thames Regional Genetics Service, London and she has a specialist interest in Ehlers–Danlos Syndrome. She was involved in setting up the UK National EDS Diagnostic Service which was established in 2009 and she has been working in the London part of the service since 2015. Dr. Serwet Demirdas, M.D., Ph.D., is a clinical geneticist in training at the Erasmus Medical Center (Erasmus University in Rotterdam, the Netherlands), where she is involved in the clinical service and research into the TNX deficient type of EDS. Prof. Sylvie Fournel-Gigleux, Pharm.D., Ph.D., is a basic researcher in biochemistry/pharmacology, Research Director at INSERM (Institut National de la Sante et de la Recherche Medicale) and co-head of the MolCelTEG Research Team at UMR 7561 CNRS-Universite de Lorraine. Her group is dedicated to the pathobiology of connective tissue disorders, in particular the Ehlers–Danlos syndromes, and specializes on the molecular and structural basis of glycosaminoglycan synthesis enzyme defects. Dr. Neeti Ghali, M.R.C.P.C.H., M.D., is a Consultant Clinical Geneticist at the North West Thames Regional Genetics Service, London and she has a specialist interest in Ehlers–Danlos Syndrome. -
Pathophysiological Significance of Dermatan
pharmaceuticals Review Pathophysiological Significance of Dermatan Sulfate Proteoglycans Revealed by Human Genetic Disorders Shuji Mizumoto 1,*, Tomoki Kosho 2, Shuhei Yamada 1 and Kazuyuki Sugahara 1,* 1 Department of Pathobiochemistry, Faculty of Pharmacy, Meijo University, 150 Yagotoyama, Tempaku-ku, Nagoya 468-8503, Japan; [email protected] 2 Center for Medical Genetics, Shinshu University Hospital, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan; [email protected] * Correspondence: [email protected] (S.M.); [email protected] (K.S.); Tel.: +81-52-839-2652 Academic Editor: Barbara Mulloy Received: 22 February 2017; Accepted: 24 March 2017; Published: 27 March 2017 Abstract: The indispensable roles of dermatan sulfate-proteoglycans (DS-PGs) have been demonstrated in various biological events including construction of the extracellular matrix and cell signaling through interactions with collagen and transforming growth factor-β, respectively. Defects in the core proteins of DS-PGs such as decorin and biglycan cause congenital stromal dystrophy of the cornea, spondyloepimetaphyseal dysplasia, and Meester-Loeys syndrome. Furthermore, mutations in human genes encoding the glycosyltransferases, epimerases, and sulfotransferases responsible for the biosynthesis of DS chains cause connective tissue disorders including Ehlers-Danlos syndrome and spondyloepimetaphyseal dysplasia with joint laxity characterized by skin hyperextensibility, joint hypermobility, and tissue fragility, and by severe skeletal disorders such as kyphoscoliosis, short trunk, dislocation, and joint laxity. Glycobiological approaches revealed that mutations in DS-biosynthetic enzymes cause reductions in enzymatic activities and in the amount of synthesized DS and also disrupt the formation of collagen bundles. This review focused on the growing number of glycobiological studies on recently reported genetic diseases caused by defects in the biosynthesis of DS and DS-PGs.